Free Trial
→ 2013 Bitcoin miner reveals his trading system (free) (From Crypto Swap Profits) (Ad)tc pixel Free JANX Stock Alerts

Janux Therapeutics (JANX) SEC Filings & 10K Form

Janux Therapeutics logo
$24.05 -1.07 (-4.26%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$24.66 +0.61 (+2.56%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Janux Therapeutics SEC Filings

Export to Excel
DateFilerForm TypeView
08/14/2025
10:26 AM		JANUS HENDERSON GROUP PLC (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G/A
08/12/2025
8:05 AM		Adage Capital Management, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G/A
07/17/2025
6:54 PM		BlackRock, Inc. (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G
06/13/2025
6:30 PM		Janux Therapeutics (Issuer)
Kung Winston (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		Janux Therapeutics (Issuer)
Simson Jake (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		Janux Therapeutics (Issuer)
McNulty Alana B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:30 PM		Barrett Ronald W (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025
6:33 PM		Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025
7:00 PM		Doyle Janeen Noel (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025
7:02 PM		Doyle Janeen Noel (Reporting)
Janux Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/14/2025
11:25 AM		JANUS HENDERSON GROUP PLC (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G/A
05/08/2025
3:30 PM		Janux Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2025
7:00 PM		Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/25/2025
3:39 PM		Janux Therapeutics (Filer)
Form DEF 14A
04/25/2025
3:40 PM		Janux Therapeutics (Filer)
Form DEFA14A
04/25/2025
3:45 PM		Janux Therapeutics (Filer)
Form ARS
04/23/2025
7:00 PM		Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2025
3:18 PM		Janux Therapeutics (Subject)
Meyer Andrew Hollman (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2025
3:33 PM		Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SCHEDULE 13D/A
03/07/2025
5:05 PM		Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2025
7:00 PM		Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2025
3:53 PM		Janux Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2025
3:55 PM		Janux Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/14/2025
3:41 PM		Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SCHEDULE 13G/A
02/14/2025
10:24 AM		JANUS HENDERSON GROUP PLC (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G
02/12/2025
8:30 AM		Adage Capital Management, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SCHEDULE 13G
02/05/2025
7:00 PM		Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2025
7:00 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:11 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
7:00 PM		Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/03/2025
7:01 PM		Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
Form 3/A
01/03/2025
7:10 PM		Dobek Maria (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM		DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM		Janux Therapeutics (Issuer)
Robinson Byron (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM		Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
7:10 PM		Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
7:00 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
9:00 AM		Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
5:25 PM		Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2024
3:32 PM		Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
3:28 PM		Janux Therapeutics (Filer)
Form 424B5
12/03/2024
7:00 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
4:10 PM		Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/27/2024
7:00 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
3:24 PM		BIOTECHNOLOGY VALUE FUND L P (Filed by)
Janux Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:58 PM		Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
11/07/2024
6:08 PM		CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2024
6:09 PM		Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2024
3:23 PM		Janux Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
3:07 PM		Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:05 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
4:02 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:24 PM		Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:30 PM		Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:17 PM		Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:07 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/30/2024
6:30 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2024
3:46 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
4:28 PM		Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/25/2024
3:57 PM		Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:44 PM		Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:51 PM		Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
11:37 AM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
10/24/2024
4:53 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
4:04 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
3:15 PM		Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
4:59 PM		Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:38 PM		Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:39 PM		Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G
10/23/2024
4:07 PM		Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
3:36 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2024
3:20 PM		Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:16 PM		Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/22/2024
3:17 PM		Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
10/21/2024
3:43 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
3:25 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
12:39 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
5:51 PM		Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
3:57 PM		Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:39 PM		Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:48 PM		Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
4:06 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:24 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:18 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
5:14 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:35 PM		Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:28 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:25 PM		Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:17 PM		Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:10 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
7:49 PM		Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2024
4:29 PM		Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
4:34 PM		Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
6:30 PM		Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
6:31 PM		DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:JANX) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel